Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study

The impact of cognitive status on outcomes of patients with atrial fibrillation (AF) is not well defined.

Background: The impact of cognitive status on outcomes of patients with atrial fibrillation (AF) is not well defined. Aims: To assess the prevalence of cognitive impairment in AF patients and evaluate its association with: i) all-cause mortality; ii) a composite endpoint of death, stroke/systemic embolism, hemorrhages, acute coronary syndrome, pulmonary embolism, new/worsening heart failure. Methods: In a cohort study, cognitive status was assessed at baseline by the Mini Mental State examination adjusted for age and education (aMMSE). aMMSE <24 was considered indicative of cognitive impairment. Results: The cohort included 437 patients (61.3% male, mean age 73.4 ± 11.7 years). Sixty-three patients (14.4%) had cognitive impairment at baseline aMMSE. Permanent AF (odds ratio [OR] 1.750; 95%CI 1.012–3.025; p =.045), haemoglobin levels (OR 0.827; 95%CI 0.707–0.967; p =.017) and previous treatment with antiplatelet drugs only, without oral anticoagulation, (OR 4.352; 95%CI 1.583–11.963; p =.004) were independently associated with cognitive impairment at baseline. After a median follow-up of 887 days (interquartile range 731–958) 30 patients died (7.1%), and 97 (22.9%) reached the composite endpoint. After adjustment for Elixhauser Comorbidy Measure, aMMSE <24 was significantly associated with all-cause mortality (hazard ratio [HR] 2.473, 95%CI 1.062–5.756, p =.036) and with the composite endpoint (HR 1.852, 95%CI 1.106–3.102, p =.019). Conclusions: In patients with AF, cognitive impairment (aMMSE <24) is associated with worse outcomes, and the association of adverse outcomes with previous treatment with antiplatelet drugs only, without oral anticoagulation, highlights the potential role of appropriate antithrombotic treatment for improving patient prognosis.